

# SPE1 Feedback session

**Dr Vikas Kapil** MA MBBS PhD FHEA FRCP FBIHS ISHF FESC



Barts & The London

# User notes

- This is a formative exam
- **Please do not share outside of your cohort**
  - This will lessen the use for future years

*If not sure about something based on the feedback or anything else PSA related, feel free to email me at [v.Kapil@qmul.ac.uk](mailto:v.Kapil@qmul.ac.uk) with your query and if we can't figure out by email, we can Teams*

# User notes

- Please use this for your learning around the topics and familiarising yourself with the BNF(s)
- The PWS questions are hand-marked
- Any truly disputable questions/answers will not have made it into a final PSA exam
- PWS (10-point prescribing) mark schemes potentially will vary in the real exam, but this is a reasonable indicative guide
- There is no reasonable way to reproduce the full “look” of the PSA exam with the Rogo/SPE system

# Summary statistics

- Internal Anghoff method pass mark **67%**
  - Fail ( $<67\%$ )
  - Borderline pass (67-70%)
  - Good pass ( $\geq 71\%$ )
- As a rule of thumb, you should do the PWS and REV questions with at least half your overall time left
- If you think you will spend too long on a calculation, I suggest you move on first
- Be familiar with the BNF
- Work through any screenshots I have provided

# Where next?

- Plenty of time to improve, regardless of current **mock** score
  - Practice materials in exam conditions (timed where possible)
  - Familiarise self with online BNFs (not just the app – it is different)
  - Suggest you work on the high scoring (10 marks) prescribing questions first
  - Please contact me ([v.kapil@qmul.ac.uk](mailto:v.kapil@qmul.ac.uk)) or Dr McGettigan ([p.mcgettigan@qmul.ac.uk](mailto:p.mcgettigan@qmul.ac.uk)) lead for CPT in MBBS, lead for PSA sessions) if want to discuss further

**Case presentation**

A 86-year-old man presents to the medical assessment unit complaining of shortness of breath at rest that has worsened over the past month. **PMH.** Ischaemic heart disease and hypertension. **DH.** Ramipril 10 mg orally daily, bisoprolol 5 mg orally daily, isosorbide mononitrate 60 mg orally daily, simvastatin 40 mg orally nightly, and aspirin 75 mg orally daily.

**On examination**

HR 105/min and regular, BP 110/70 mmHg, JVP elevated at 6 cm, RR 30/min, O<sub>2</sub> sat 93% on air. Examination of the chest reveals dullness to percussion both bases and fine inspiratory crackles in both lower zones. Bilateral swollen legs with pitting oedema to knees.

**Investigations**

Na<sup>+</sup> 141 mmol/L (137–144), K<sup>+</sup> 4.2 mmol/L (3.5–4.9), U 7.0 mmol/L (2.5–7.0), Cr 100 µmol/L (60–110).

An intravenous infusion of GTN and supplementary oxygen have been initiated.

**Prescribing request**

Write a prescription for ONE drug that will help to relieve his fluid overload and breathlessness.  
(use the hospital 'once-only medicines' prescription chart provided)

**ONCE ONLY MEDICINES**

| Date | Time | Medicine (Approved name) | Dose | Route | Prescriber – sign + print | Time given | Given by |
|------|------|--------------------------|------|-------|---------------------------|------------|----------|
|      |      |                          |      |       |                           |            |          |
|      |      |                          |      |       |                           |            |          |
|      |      |                          |      |       |                           |            |          |
|      |      |                          |      |       |                           |            |          |

| A. Drug choice |                       |   | Score | Feedback/justification                                                                                  | B. Dose and route            |   |  | Score | Feedback/justification                                                                                                    |
|----------------|-----------------------|---|-------|---------------------------------------------------------------------------------------------------------|------------------------------|---|--|-------|---------------------------------------------------------------------------------------------------------------------------|
| 1              | Furosemide            | 5 |       | This is a powerful loop diuretic and is one of the drugs most likely to achieve a significant diuresis. | 40–120 mg IV                 | 5 |  |       | This dose and route would be likely to achieve a significant diuresis (doses > 50 mg should be given by slow IV infusion) |
| 2              |                       |   |       |                                                                                                         | <40 mg IV                    | 2 |  |       | This dose may produce a suboptimal diuresis                                                                               |
| 3              |                       |   |       |                                                                                                         | >120 mg IV                   | 2 |  |       | This is an unnecessarily high dose of furosemide that risks causing adverse effects in a diuretic naïve patient           |
| 4              |                       |   |       |                                                                                                         | 20 mg oral                   | 1 |  |       | This dose is unlikely to be effective                                                                                     |
| 5              |                       |   |       |                                                                                                         | 40–120 mg oral               | 2 |  |       | Any oral route will be less effective than IV                                                                             |
| 6              |                       |   |       |                                                                                                         | >120 mg oral                 | 1 |  |       | This dose is excessive and the route would be less likely to achieve a significant diuresis                               |
| 7              | Bumetanide            | 5 |       | Loop diuretic. Not as commonly used in intravenous form as furosemide                                   | 1–3 mg IV                    | 5 |  |       | This dose and route would be likely to achieve a significant diuresis                                                     |
| 8              |                       |   |       |                                                                                                         | <1 mg IV                     | 2 |  |       | This dose runs a significant danger of producing a suboptimal diuresis                                                    |
| 9              |                       |   |       |                                                                                                         | >3 mg IV                     | 2 |  |       | This is an unnecessarily high dose of bumetanide that risks causing adverse effects in a diuretic naïve patient           |
| 10             |                       |   |       |                                                                                                         | 1-2 mg oral                  | 2 |  |       | Any oral route will be less effective than IV                                                                             |
| 11             |                       |   |       |                                                                                                         | oral dose outside this range | 1 |  |       | This dose and route are inappropriate                                                                                     |
| 12             | Torsemide             | 2 |       | This is a powerful loop diuretic but is available only via the oral route                               | 5 – 40 mg oral               | 2 |  |       | This is the correct dose of torsemide but a parenteral loop diuretic should have been chosen                              |
| 13             | Any thiazide diuretic | 1 |       | This is a thiazide diuretic, which will not have sufficient efficacy to achieve a significant diuresis  | Correct dose and route       | 1 |  |       | This is the correct dose but a parenteral loop diuretic should have been chosen                                           |
| 14             | Any other diuretic    | 0 |       | This kind of diuretic will not have sufficient efficacy to achieve a significant diuresis               |                              |   |  |       |                                                                                                                           |
| 15             | Nitrates              | 0 |       | The patient is already being given a nitrate                                                            |                              |   |  |       |                                                                                                                           |
| 16             | Morphine/diamorphine  | 1 |       | May redistribute fluid but will not improve fluid overload                                              | 2.5–10 mg/2.5–5 mg IV        | 1 |  |       | Higher doses would be hazardous (0 marks)                                                                                 |

**Marking guide for A and B.** Candidates should be given **5 marks** for an optimal answer that can't be improved. They should get **3 marks** for an answer that is good but is suboptimal on some grounds (e.g. cost-effectiveness, likely adherence). They should get **2 marks** for an answer that is likely to provide benefit but is clearly suboptimal for more than one reason. They should get **1 mark** for an answer that has some justification and deserves some credit.

# Acute heart failure

- Need to be familiar with diuretics in context of
  - Acute vs Chronic
    - Loop diuretics (e.g. furosemide) are the option of choice in **acute** heart failure
      - Dose typically 40-80mg, but sometimes can be higher
    - A small minority chose a thiazide-like diuretic
      - This will not be rapid-acting (esp as it would be given orally)
    - A small minority chose spironolactone
      - This is for chronic heart failure with reduced ejection fraction
  - IV vs oral loop diuretic
    - IV route is option of choice in **acute** heart failure
    - Lots chose oral diuretics
      - IV has quicker onset
    - A smaller minority chose intramuscular furosemide
      - Furosemide is rarely/never given I/M and is inappropriate route

Case presentation

A 13-year-old boy is assessed on the paediatric day unit for severe aural pain that has not improved despite 72 hours of treatment with simple analgesia. **PMH.** None. **DH.** Paracetamol 1 g orally as required. Allergic to penicillin.

On examination

T 37.7 °C; HR 100/min; BP 100/68 mmHg. Otoscopy reveals intact red drum, bulging on right side. He weighs 50kg

Prescribing request

Write a prescription for ONE drug that will treat his infection.  
*(use the hospital ‘regular medicines’ prescription chart provided)*

|                           |            |      |  |  |  |  |  |
|---------------------------|------------|------|--|--|--|--|--|
|                           |            | Date |  |  |  |  |  |
|                           |            | Time |  |  |  |  |  |
| Drug (Approved name)      |            | 6    |  |  |  |  |  |
|                           |            | 8    |  |  |  |  |  |
| Dose                      | Route      | 12   |  |  |  |  |  |
| Prescriber – sign + print | Start date | 14   |  |  |  |  |  |
| Notes                     | Pharmacy   | 18   |  |  |  |  |  |
|                           |            | 22   |  |  |  |  |  |

Prescribing  
Item

Answer Page

ID

PWS203

This item is worth 10 marks

You may use the  
BNF at any time

| A. Drug choice |                                              |       |                                                                         | B. Dose and Posology                                                      |       |                                                   |  |
|----------------|----------------------------------------------|-------|-------------------------------------------------------------------------|---------------------------------------------------------------------------|-------|---------------------------------------------------|--|
|                |                                              | Score | Feedback/justification                                                  |                                                                           | Score | Feedback/justification                            |  |
| 1              | Clarithromycin                               | 5     | BNF recommended 1 <sup>st</sup> line for penicillin allergy             | 250 mg 12-hrly orally                                                     | 5     | Recommended dose/posology                         |  |
| 2              |                                              |       |                                                                         | 500mg 12-hrly orally                                                      | 3     | Usually reserved for severe infections            |  |
| 3              |                                              |       |                                                                         | 500mg 12-hrly iv                                                          | 1     | Parenteral reserved for serious or systemic upset |  |
| 4              |                                              |       |                                                                         | Any other dose/timing/route                                               | 0     |                                                   |  |
| 5              | Other macrolide (erythromycin, azithromycin) | 5     | Acceptable as first line in penicillin allergy in newer versions of BNF | Erythromycin 250mg 6-hrly orally<br>Erythromycin 500mg orally twice daily | 5     | Recommended dose/posology                         |  |
| 6              |                                              |       |                                                                         | Erythromycin 500mg 6-hrly orally or 1000mg twice daily                    | 3     | Usually reserved for severe infections            |  |
| 7              |                                              |       |                                                                         | Any IV dose                                                               | 1     | Parenteral reserved for serious or systemic upset |  |
| 8              | Beta lactam antibiotic                       | 0     | POTENTIALLY LIFE-THREATENING                                            | Any dose of beta-lactam                                                   | 0     | POTENTIALLY LIFE-THREATENING                      |  |

**Marking guide for A and B.** Candidates should be given **5 marks** for an optimal answer that can't be improved. They should get **3 marks** for an answer that is good but is suboptimal on some grounds (e.g. cost-effectiveness, likely adherence). They should get **2 marks** for an answer that is likely to provide benefit but is clearly suboptimal for more than one reason. They should get **1 mark** for an answer that has some justification and deserves some credit.

# Antibiotics

- Be familiar with how to look up empirical antibiotic therapy on BNFs
  - Two options shown in following slides
- **Principles**
  - Check pregnancy status and allergies for contraindications
    - 80% chose an oral macrolide
    - **Check allergies!**
    - Check renal function (sometimes age, weight, liver function) for possible dose adjustment
  - Decide on the infection you are aiming to treat
  - Decide on “severity” of infection for correct dose and IV/PO
  - Check other patient details for route
    - E.g. unable to swallow, poor absorption → likely IV route
    - Whenever possible, painful IM injections should be avoided in children
  - Based on sensitivities if possible

Read about [our approach to COVID-19](#)

[NICE](#) > [BNF](#) > Search results for otitis media

# BNF search result

Showing 1 to 10 of 23 results for ot

[Ear](#) | [Treatment summary](#)

**Otitis externa** **Otitis externa** refers to inflammatory some cases may involve oedema. It...

[Ear infections, antibacterial therapy](#) | [Trea](#)

**Otitis externa** **Otitis externa** is inflammation of th triggered by a bacterial infection...

## Otitis media

Acute otitis media is inflammation in the middle ear associated with effusion and accompanied by an ear infection. Acute otitis media is commonly seen in children and is generally caused by viruses (respiratory syncytial virus, influenza virus, and parainfluenza virus) or bacteria (*Streptococcus pneumoniae*, *Streptococcus p*, *Haemophilus influenzae*). Virus and bacteria often co-exist. For further i

## Choice of antibacterial the

### No penicillin allergy

- *First line:* [amoxicillin](#).
- *Second line* (worsening symptoms despite [amoxiclav](#)).

### Penicillin allergy or intolerance

- *First line:* [clarithromycin](#) or [erythromycin](#) (ir
- *Second line* (worsening symptoms despite consult local microbiologist).

### Acute **otitis media**

By mouth using immediate-release medicines

- **Child 1 month–11 years (body-weight up to 8 kg)**  
7.5 mg/kg twice daily for 5–7 days.
- **Child 1 month–11 years (body-weight 8–11 kg)**  
62.5 mg twice daily for 5–7 days.
- **Child 1 month–11 years (body-weight 12–19 kg)**  
125 mg twice daily for 5–7 days.
- **Child 1 month–11 years (body-weight 20–29 kg)**  
187.5 mg twice daily for 5–7 days.
- **Child 1 month–11 years (body-weight 30–40 kg)**  
250 mg twice daily for 5–7 days.
- **Child 12–17 years**  
250–500 mg twice daily for 5–7 days.
- **Adult**  
250 mg twice daily usually for 7–14 days, increased to 500 mg twice daily, if required in severe infections.

**Case presentation**

A 40-year-old man was brought to the Emergency Department after a bystander found him with reduced consciousness. He was found to be hypoglycaemic by the paramedics and has received glucagon 1 mg intramuscularly 10 minutes ago.

**On examination**

Temperature 37.1°C, HR 110/min and regular, BP 121/73 mmHg, O<sub>2</sub> sat 99% on 15L oxygen. GCS 6/15. Appears cachectic.

**Investigations**

Capillary blood glucose 2.1 mmol/L, ECG sinus rhythm, CXR clear lung fields.

**Prescribing request**

Write a prescription for ONE intravenous fluid that would be most appropriate for the patient at this point.  
(use the hospital fluid prescription chart provided)

| INFUSION THERAPY |            |                   |        |       |      |          |                |      |                        |          |
|------------------|------------|-------------------|--------|-------|------|----------|----------------|------|------------------------|----------|
| Date             | Start time | Infusion solution |        |       |      |          | Medicine added |      | Prescriber's signature | Given by |
|                  |            | Type/strength     | Volume | Route | Rate | Duration | Approved name  | Dose |                        |          |
|                  |            |                   |        |       |      |          |                |      |                        |          |
|                  |            |                   |        |       |      |          |                |      |                        |          |
|                  |            |                   |        |       |      |          |                |      |                        |          |

| A. Drug choice |                            |       |                                                      | B. Dose and Posology                    |  |       |                                    |
|----------------|----------------------------|-------|------------------------------------------------------|-----------------------------------------|--|-------|------------------------------------|
|                |                            | Score | Feedback/justification                               |                                         |  | Score | Feedback/justification             |
| 1              | Glucose 10%                | 5     | BNF recommended 1 <sup>st</sup> line fluid           | 150mL-200mL over 15min                  |  | 5     | Recommended dose/posology (15-20g) |
| 2              |                            |       |                                                      | >200ml IV                               |  | 2-3   | Increased risk of phlebitis        |
| 3              |                            |       |                                                      | <150mL IV                               |  | 1     | May not be effective               |
| 4              |                            |       |                                                      | Any >15 minutes –2 marks                |  |       |                                    |
| 5              | Glucose 20%                | 4     | BNF 1 <sup>st</sup> line (equal) for unconsciousness | 75mL-100mL over 15min                   |  | 5     | 15-20g                             |
| 6              |                            |       |                                                      | Rest of mark scheme similar to above    |  |       |                                    |
| 7              | Glucose 50%                | 1     | More likely phlebitis                                | 30-40mL over 15min or less              |  | 1     | 15-20g                             |
| 8              |                            |       |                                                      | Rest of mark scheme similar to above    |  |       |                                    |
| 9              | Glucose 5% or Dextrosaline | 0     | Unlikely to be very effective                        | Any dose of 5% dextrose or dextrosaline |  | 0     | May increase CBG a tiny amount     |
| 10             | Any other fluid            | 0     | POTENTIALLY LIFE-THREATENING                         | Any other fluid volume                  |  | 0     | POTENTIALLY LIFE-THREATENING       |

**Marking guide for A and B.** Candidates should be given **5 marks** for an optimal answer that can't be improved. They should get **3 marks** for an answer that is good but is suboptimal on some grounds (e.g. cost-effectiveness, likely adherence). They should get **2 marks** for an answer that is likely to provide benefit but is clearly suboptimal for more than one reason. They should get **1 mark** for an answer that has some justification and deserves some credit.

# Hypoglycaemia

- NOTE: This is **not** a typical fluids prescription question for the PSA, but is important learning topic
- Hypoglycaemia management
  - Alert
    - Glucose 15-20 g orally in liquid form followed by sustained carbohydrate
  - Reduced consciousness
    - Glucagon (1mg subcutaneously or intramuscularly)
    - Alternatively (or if no response to glucagon), 10% glucose intravenously to give 15-20g over 15 min
  - Unconscious
    - Glucagon (1mg subcutaneously or intramuscularly)
    - Alternatively (or if no response to glucagon), 10 or 20% glucose intravenously to give 15-20g over 15 min

In an emergency, if the patient has a **hypoglycaemia**, intramuscular **glucagon** has been shown how to use it. If **glucose** 10% intravenous infusion should be given.

Hypoglycaemia which causes **unconscious**, having seizures, or who has had insulin stopped, and be treated initially. If there is no response after 10 minutes, alternatively **glucose** 20% intravenous infusion is not recommended. Extravasation injury, and is viscous, may

## Hypoglycaemia

By mouth

### Child up to 5 years

5 g, repeated after 15 minutes if necessary, 5 g is available from 20 mL oral glucose liquid, 1.5 glucose tablets, or half a tube of glucose 40% oral gel. If oral glucose formulations are not available, the dose may be given using another fast-acting carbohydrate; 5 g is available from approximately 1 teaspoonful of sugar dissolved in an appropriate volume of water.

### Child 5–11 years

10 g, repeated after 15 minutes if necessary, 10 g is available from 40 mL oral glucose liquid, 3 glucose tablets, or 1 tube of glucose 40% oral gel. If oral glucose formulations are not available, the dose may be given using another fast-acting carbohydrate; 10 g is available from approximately 2 teaspoonfuls of sugar dissolved in an appropriate volume of water.

### Child 12–17 years

15 g, repeated after 15 minutes if necessary, 15 g is available from 60 mL oral glucose liquid, 4 glucose tablets, or 1.5 tubes of glucose 40% oral gel. If oral glucose formulations are not available, the dose may be given using another fast-acting carbohydrate; 15 g is available from approximately 3 teaspoonfuls of sugar dissolved in an appropriate volume of water.

### Adult

15–20 g, repeated after 15 minutes if necessary, 15–20 g is available from 60–80 mL oral glucose liquid, 4–5 glucose tablets, or 1.5–2 tubes of glucose 40% oral gel. If oral glucose formulations are not available, the dose may be given using another fast-acting carbohydrate; 15–20 g is available from approximately 3–4 teaspoonfuls of sugar dissolved in an appropriate volume of water, or 150–200 mL of pure fruit juice.

By intravenous infusion

### Child

500 mg/kg, to be administered as Glucose 10% intravenous infusion into a large vein through a large-gauge needle; care is required since this concentration is irritant.

### Adult

15–20 g, to be administered over 15 minutes as Glucose 10% or 20% intravenous infusion into a large vein

# Hypoglycaemia

- Example correct answers below:  
150-200mL 10% glucose

[illegible]

# Hypoglycaemia

- Common errors:

- Using non-glucose based fluids

- ?not recognising the hypoglycaemic episode

- 50% glucose too concentrated

- risk of extravasation injury

- Choosing a time >15min

- Being an emergency, it should be given relatively fast  
(over 15min)

# Hypoglycaemia

- Example of other common errors:

| INFUSION THERAPY |            |                      |        |       |      |          |                |      |                        |          |
|------------------|------------|----------------------|--------|-------|------|----------|----------------|------|------------------------|----------|
| Date             | Start time | Infusion solution    |        |       |      |          | Medicine added |      | Prescriber's signature | Given by |
|                  |            | Type/strength        | Volume | Route | Rate | Duration | Approved name  | Dose |                        |          |
| 21/9             | 16:00      | Sodium chloride 0.9% | 500 ml | IV    |      | 15min    | Glucose 15g    |      | VK                     |          |
|                  |            |                      |        |       |      |          |                |      |                        |          |
|                  |            |                      |        |       |      |          |                |      |                        |          |

- Glucose is not an added drug, it is a fluid of it's own

# Hypoglycaemia

- Example of other common errors:

| INFUSION THERAPY |            |                   |        |       |      |          |                |      |                        |          |
|------------------|------------|-------------------|--------|-------|------|----------|----------------|------|------------------------|----------|
| Date             | Start time | Infusion solution |        |       |      |          | Medicine added |      | Prescriber's signature | Given by |
|                  |            | Type/strength     | Volume | Route | Rate | Duration | Approved name  | Dose |                        |          |
| 21/11            | 16:00      | Glucose 10%       | 15g    | IV    |      | 15       |                |      | VK                     |          |
|                  |            |                   |        |       |      |          |                |      |                        |          |
|                  |            |                   |        |       |      |          |                |      |                        |          |

- Although the final content is 15g, it should be prescribed as a volume (75ml in this case to give 15g glucose)

Write a prescription for ONE drug will help reduce the risk of further fractures.  
(use the general practice prescription form provided)

|                                                         |                                                                                |                                                                                                         |
|---------------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Pharmacy Stamp                                          | Age<br>0yr 0mths<br>D.o.B.<br>00/00/0000                                       | Title, Forename, Surname & Address<br>Patient Name<br>Address Line 1<br>Address Line 2<br>Town Postcode |
| Number of days' treatment<br>N.B. Ensure dose is stated |                                                                                | 28                                                                                                      |
| Endorsements                                            | Drug Name<br>Dose<br>Frequency                                                 |                                                                                                         |
| Signature of Prescriber<br>Signature                    |                                                                                | Date<br>00/00/0000                                                                                      |
| For<br>Dispenser<br>No. of<br>Prescsns.<br>on form      | Xxxxx Health Authority<br>Dr<br>Address<br>Town Postcode<br>Tel: 00000 000 000 |                                                                                                         |
|                                                         | FP10NC0105                                                                     |                                                                                                         |

| A. Drug choice        |                                  | Score | Feedback/justification                                                                                   | B. Dose and Posology                                       |                                            | Score                                                             | Feedback/justification |
|-----------------------|----------------------------------|-------|----------------------------------------------------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------|-------------------------------------------------------------------|------------------------|
| 1                     | Alendronic Acid                  | 5     | BNF recommended 1 <sup>st</sup> line for post menopausal, secondary prevention of osteoporotic fractures | 70mg ORAL once-weekly or                                   | 5                                          | Recommended dose                                                  |                        |
| 10mg once-daily       |                                  |       |                                                                                                          | 3                                                          | Recommended dose but not ideal for patient |                                                                   |                        |
| 10mg ORAL once-weekly |                                  |       |                                                                                                          | 1                                                          | Too low                                    |                                                                   |                        |
| 70mg ORAL daily       |                                  |       |                                                                                                          | 0                                                          | Danger of toxicity                         |                                                                   |                        |
| Other doses           |                                  |       |                                                                                                          | 0                                                          | (not readily available)                    |                                                                   |                        |
| 2                     | Risedronate                      | 5     | Now joint 1 <sup>st</sup> line for post menopausal, secondary prevention of osteoporotic fractures       | ORAL 35mg weekly                                           | 5                                          | Recommended dose                                                  |                        |
| 5mg ORAL daily        |                                  |       |                                                                                                          | 3                                                          | Recommended dose but not ideal for patient |                                                                   |                        |
| 5mg ORAL weekly       |                                  |       |                                                                                                          | 1                                                          | Too low                                    |                                                                   |                        |
| 35mg ORAL daily       |                                  |       |                                                                                                          | 0                                                          | Danger of toxicity                         |                                                                   |                        |
| Other doses           |                                  |       |                                                                                                          | 0                                                          | (not readily available)                    |                                                                   |                        |
| 3                     | Strontium ranelate<br>Raloxifene | 2     | 3 <sup>rd</sup> line for post menopausal, secondary prevention of osteoporotic fractures                 | Strontium (ORAL 2g daily),<br>raloxifene (ORAL 60mg daily) | 2                                          | Correct doses (any other dose = 0 marks as not readily available) |                        |
| 4                     | Teriparatide                     | 1     | 4 <sup>th</sup> line for post menopausal, secondary prevention of osteoporotic fractures                 | 20 micrograms SC daily                                     | 1                                          |                                                                   |                        |
| 5                     | Other bisphosphonates            | 2     | Not recommended for osteoporosis orally                                                                  | Correct dose of other bisphosphonates                      | 2                                          |                                                                   |                        |
| 6                     | HRT<br>Calcitriol                | 1     | Recommended for corticosteroid induced osteoporosis as 2 <sup>nd</sup> line to bisphosphonates           | Correct dose of HRT/calcitriol                             | 1                                          |                                                                   |                        |

**Marking guide for A and B.** Candidates should be given **5 marks** for an optimal answer that can't be improved. They should get **3 marks** for an answer that is good but is suboptimal on some grounds (e.g. cost-effectiveness, likely adherence). They should get **2 marks** for an answer that is likely to provide benefit but is clearly suboptimal for more than one reason. They should get **1 mark** for an answer that has some justification and deserves some credit.

# PWS general lesson

- Prescribe what you commonly see prescribed!
- Alendronic acid
  - Although 10mg daily and 70mg weekly are BOTH licenced,
  - Commonly accepted that 70mg weekly is more convenient for patients
- Not using second-line drugs unless good reason

**Case presentation**

A 53-year-old woman is admitted to hospital with a non-infective exacerbation of her chronic obstructive pulmonary disease. **PMH.** Alcohol dependence (up to 60 units/day), atrial fibrillation, chronic obstructive pulmonary disease, rheumatoid arthritis, type II diabetes. **DH.** In addition apixaban 5 mg orally 12hrly, her medications are listed right.

**Question A**

Select the TWO prescriptions that are least likely be efficacious at the current prescribed dose.  
(mark them with a tick in column A)

**Question B**

Select the ONE prescriptions that should not be prescribed together with her apixaban  
(mark them with a tick in column B)

**CURRENT PRESCRIPTIONS**

| Drug name           | Dose           | Route | Freq.       | A                                   | B                                   |
|---------------------|----------------|-------|-------------|-------------------------------------|-------------------------------------|
| Azathioprine        | 100 mg         | ORAL  | Daily       | <input type="checkbox"/>            | <input type="checkbox"/>            |
| Chlordiazepoxide    | 10 mg          | ORAL  | Daily       | <input checked="" type="checkbox"/> | <input type="checkbox"/>            |
| Dalteparin          | 5000 units     | S.C.  | Daily       | <input type="checkbox"/>            | <input checked="" type="checkbox"/> |
| Ipratropium bromide | 250 micrograms | NEBS  | 6-hrly      | <input type="checkbox"/>            | <input type="checkbox"/>            |
| Metformin MR        | 1 gram         | ORAL  | Twice daily | <input type="checkbox"/>            | <input type="checkbox"/>            |
| Prednisolone        | 40 mg          | ORAL  | Daily       | <input type="checkbox"/>            | <input type="checkbox"/>            |
| Salbutamol          | 200 micrograms | NEBS  | 6-hrly      | <input checked="" type="checkbox"/> | <input type="checkbox"/>            |
| Symbicort® 100/6    | Two puffs      | INH.  | 12-hrly     | <input type="checkbox"/>            | <input type="checkbox"/>            |

**Answer box**

**Question A** Marks per correct tick 1

Chlordiazepoxide at 10mg orally daily is unlikely to be sufficient for the degree of alcohol dependence.  
Salbutamol nebulisers are typically prescribed at 2.5mg (or occasionally 5mg) for each nebulizer – whereas the 200micrograms dose is typical for inhalers

**Question B** Marks per correct tick 2

LWMH for DVT prophylaxis should not be used together with anticoagulation (be it DOAC or warfarin)

### Case presentation

A 63-year-old man returns to his General Practitioner to review his medications prior to a repeat prescription. **PMH.** Gout, *H. pylori*-associated gastritis three months ago, ischaemic heart disease, Type II diabetes mellitus. **DH.** Listed on table.

### Question A

Select the THREE prescriptions that should be prescribed for a short duration.  
(mark them with a tick in column A)

### Question B

Select the ONE prescription that has a dosing error.  
(mark it with a tick in column B)

### CURRENT PRESCRIPTIONS

| Drug name      | Dose   | Route | Freq.   |
|----------------|--------|-------|---------|
| Allopurinol    | 200 mg | ORAL  | daily   |
| Amoxicillin    | 1 g    | ORAL  | 12-hrly |
| Aspirin        | 75 mg  | ORAL  | daily   |
| Bisoprolol     | 10 mg  | ORAL  | daily   |
| Clarithromycin | 500 mg | ORAL  | 12-hrly |
| Gliclazide     | 4 mg   | ORAL  | 12-hrly |
| Metformin M/R  | 2 g    | ORAL  | evening |
| Omeprazole     | 20 mg  | ORAL  | 12-hrly |
| Ramipril       | 10 mg  | ORAL  | daily   |

| A                                   | B                                   |
|-------------------------------------|-------------------------------------|
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> |
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input type="checkbox"/>            |

### Answer box

**Question A** Marks per correct tick 1

*H. Pylori* eradication therapy should be reviewed to consider whether it is appropriate to stop

**Question B** Marks per correct tick 2

Gliclazide 4mg 12-hrly is typically a sub-therapeutic dose, and usually prescribed between 40mg and 160mg

### Case presentation

A 66-year-old man attends his annual diabetic review. He has been well and asymptomatic since his last review.

**PMH.** Type II diabetes mellitus, gout, hypercholestromlaemia, hypertension.  
He provides a hand-written list of medications he believe he is taking (see right).

### Question A

Select the TWO prescriptions that is *most likely* contribute to hypoglycaemia.  
(mark them with a tick in column A)

### Question B

Select the ONE prescription that has a dosing error.  
(mark it with a tick in column B)

### CURRENT PRESCRIPTIONS

| Drug name      | Dose   | Route | Freq.                  |
|----------------|--------|-------|------------------------|
| Allopurinol    | 100 mg | ORAL  | Daily                  |
| Amlodipine     | 10 mg  | ORAL  | Daily                  |
| Bezafibrate    | 400 mg | ORAL  | At night               |
| Canagliflozin  | 200 mg | ORAL  | Daily                  |
| Glimepride     | 1 mg   | ORAL  | Daily                  |
| Metformin      | 1 mg   | ORAL  | Lunch and evening meal |
| Pioglitazone   | 45 mg  | ORAL  | Daily                  |
| Simvastatin    | 40 mg  | ORAL  | At night               |
| Spironolactone | 25 mg  | ORAL  | Daily                  |

| A                                   | B                                   |
|-------------------------------------|-------------------------------------|
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> |
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input type="checkbox"/>            |

### Answer box

**Question A** Marks per correct tick 1

Insulin, sulfonylureas and SGLT2 inhibitors all carry a risk of hypoglycaemia  
Thiazolidinediones (pioglitazone) also carries this risk, but is lower than the other two listed here.

**Question B** Marks per correct tick 2

Metformin is prescribed between 500mg and 2g

### Case presentation

A 79-year-old woman presents to the emergency room after a fall. X-ray of her left hip confirms a fractured neck of femur. On examination you notice she has broken skin from scratch marks along both her arms (which appear quite thin compared to the rest of her rotund body). Even her face appears round. When asked why she fell, she tells you she felt dizzy two hours after taking her tablets. **PMH.** Hypertension, type 2 diabetes mellitus, giant cell arteritis. **DH.** Her current regular medicines are listed (right).

### Investigations

Full blood count normal, U+E normal, capillary blood glucose 6.2 mmol/L.

### Question A

Select the *TWO* medications that raised her likelihood of fracture.  
(mark it with a tick in column A)

### Question B

Select the *TWO* medications that are *most likely* to be contributing to the dizzy feeling which led to her fall.  
(mark it with a tick in column B)

### CURRENT PRESCRIPTIONS

| Drug name     | Dose   | Route | Freq.   |
|---------------|--------|-------|---------|
| Aspirin       | 75 mg  | ORAL  | Daily   |
| Empagliflozin | 10 mg  | ORAL  | Daily   |
| Gaviscon      | 10 ml  | ORAL  | PRN     |
| Metformin     | 500 mg | ORAL  | 12-hrly |
| Omeprazole    | 40 mg  | ORAL  | Daily   |
| Prednisolone  | 15 mg  | ORAL  | Daily   |
| Ramipril      | 10 mg  | ORAL  | Daily   |
| Senna         | 15 mg  | ORAL  | Nightly |
| Simvastatin   | 20 mg  | ORAL  | Daily   |

| A                                   | B                                   |
|-------------------------------------|-------------------------------------|
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> |
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> |
| <input type="checkbox"/>            | <input type="checkbox"/>            |
| <input type="checkbox"/>            | <input type="checkbox"/>            |

### Answer box

**Question A** Marks per correct tick [1]

Prednisolone in this dose is common for those with giant cell arteritis. However, steroids in high doses taken regularly without bone protection can make bones easier to fracture.

**Question B** Marks per correct tick [1]

Empagliflozin and ramipril-associated hypotension can make the patient feel dizzy and lead to falls.  
Metformin would not be implicated as it will not cause a hypoglycaemic episode.  
(GI bleed a possibility as on steroid and NSAID but urea and haemoglobin normal)

### Case presentation

A 32-year-old woman develops postpartum haemorrhage relating to uterine atony. **PMH.** Nil **DH.** Folic acid and ferrous sulfate supplements.

### On examination

Temperature 36.8°C, HR 96/min and regular, BP 114/66 mmHg, RR 22/min, O<sub>2</sub> sats 97% (94–98) breathing air. Ongoing PV bleeding.

Volume resuscitation has been initiated, and potential blood transfusion has been arranged.

### Question

Select the *most appropriate* management option at this stage.  
(mark it with a tick)

## MANAGEMENT OPTIONS

|          |                                                                    |                                     |
|----------|--------------------------------------------------------------------|-------------------------------------|
| <b>A</b> | Noradrenaline infusion, adjusted to blood pressure response        | <input type="checkbox"/>            |
| <b>B</b> | Oxytocin 5 units intravenously by slow injection                   | <input checked="" type="checkbox"/> |
| <b>C</b> | Salbutamol 5 mg intravenously by slow infusion                     | <input type="checkbox"/>            |
| <b>D</b> | Terbutaline sulfate 100 micrograms intravenously by slow injection | <input type="checkbox"/>            |
| <b>E</b> | Tranexamic acid 1 g intravenously by slow injection                | <input type="checkbox"/>            |

## Answer box

### Option A Justification

There is currently no immediate need for inotropic / blood pressure support. Inotropic support may be indicated if haemodynamics are not maintained with fluid resuscitation alone

### Option B Justification

Oxytocin (or ergometrine) may be used in uterine atony

### Option C Justification

Salbutamol is an option for tocolysis. Reducing uterine tone can worsen postpartum haemorrhage

### Option D Justification

Terbutaline is a beta2 adrenoreceptor agonist, and used as a tocolytic. Use in this case will exacerbate the postpartum haemorrhage

### Option E Justification

Tranexamic acid is useful for menorrhagia as an antifibrinolytic agent, but not of use in uterine atony

# “I know nothing about O+G!”

- This is a good example of how to look for a management plan
  - The following suggestions however do not always work!
  - If you think you already know the answer, go for it!
  - DO NOT SPEND TIME YOU DON'T HAVE SEARCHING!
- Also be aware that there are potentially different search terms
  - “Postpartum haemorrhage”?
  - “Uterine atony”?
  - (For example, “hypokalaemia” is also “potassium loss”)

### Case presentation

A 34-year-old woman with a history of asthma is visiting her General Practitioner for worsening of her asthma control. She now requires up to three puffs of salbutamol as a reliever per day.  
**DH.** Salbutamol inhaler as required, beclometasone dipropionate 400 micrograms inhaled 12-hrly.

Compliance and inhaler technique has been checked to be good, and trigger factors have been addressed.

### Question

Select the *most appropriate* management option at this stage.  
(mark it with a tick)

### MANAGEMENT OPTIONS

|          |                                                              |                                     |
|----------|--------------------------------------------------------------|-------------------------------------|
| <b>A</b> | Add ipratropium bromide 20 micrograms inhaled 6-hrly         | <input type="checkbox"/>            |
| <b>B</b> | Add monteleukast 10mg orally once daily                      | <input checked="" type="checkbox"/> |
| <b>C</b> | Add prednisolone 30 mg orally daily                          | <input type="checkbox"/>            |
| <b>D</b> | Add salmeterol 50 micrograms inhaled 12-hrly                 | <input type="checkbox"/>            |
| <b>E</b> | Increase beclomethasone dipropionate to 1 mg inhaled 12-hrly | <input type="checkbox"/>            |

### Answer box

#### Option A Justification

Ipratropium is not typically used in chronic asthma (and not as Step 3)

#### Option B Justification

For NICE guidance (see later re: NICE vs BTS), monteleukast is appropriate for step 2

#### Option C Justification


Oral prednisolone is typically used in acute exacerbations, or as Step 5 therapy

#### Option D Justification

This is an may be considered as Step 3 treatment for NICE guidance


#### Option E Justification

| Asthma - suspected       | Asthma - diagnosed                                                                                                                                                                                                               |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Diagnosis and assessment | Evaluation: <ul style="list-style-type: none"> <li>•assess symptoms, measure lung function, check Inhaler technique and adherence</li> <li>•adjust dose •update self-management plan •move up and down as appropriate</li> </ul> |



| Asthma - suspected       | Asthma - diagnosed                                                                                                                                                                                                               |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Diagnosis and assessment | Evaluation: <ul style="list-style-type: none"> <li>•assess symptoms, measure lung function, check Inhaler technique and adherence</li> <li>•adjust dose •update self-management plan •move up and down as appropriate</li> </ul> |

**BTS 2016**



**Inhaled short-acting beta2-agonists – consider step up if  $\geq 3$  use/week**

### Case presentation

A 72-year-old man with metastatic lung cancer is being treated for palliative symptom control. His only current symptom is severe nausea and vomiting. He is unable to tolerate liquids or tablets.

### Question

Select the *most appropriate* management option at this stage.  
(mark it with a tick)

### MANAGEMENT OPTIONS

|   |                                                           |                                     |
|---|-----------------------------------------------------------|-------------------------------------|
| A | Cyclizine 50 mg intravenously as required                 | <input type="checkbox"/>            |
| B | Diamorphine 20 mg subcutaneously over 24 hours            | <input type="checkbox"/>            |
| C | Haloperidol 2.5 mg subcutaneously over 24 hours           | <input checked="" type="checkbox"/> |
| D | Hyoscine butylbromide 1.2 mg subcutaneously over 24 hours | <input type="checkbox"/>            |
| E | Ondansetron 8 mg orally 12-hrly                           | <input type="checkbox"/>            |

### Answer box

#### Option A Justification

Although cyclizine may appropriate in this case, the intravenous route and “as required” frequency may not be best

#### Option B Justification

Diamorphine is used for predominantly pain management, and may worsen the nausea.

#### Option C Justification

This is an appropriate subcutaneous dose , and this route may be most appropriate with a syringe driver

#### Option D Justification

Hyoscine bytylbromide is used for bowel colic and excessive secretions in palliative care

#### Option E Justification

Oral medications are not appropriate with the severity of his symptoms.

# Palliative prescribing

- Key principles
  - Number of drugs should be as few as possible
  - Oral medication can be satisfactory unless there is severe nausea and vomiting, dysphagia, weakness, or coma
  - Sometimes consider patches
    - For medium-to-long-term analgesia
    - **Not** for end-of-life care
    - Not easy to titrate
  - End-of-life care typically uses subcutaneous prescriptions either as required, or in continuous (24hr) syringe driver. Especially if
    - The patient is unable to take medicines by mouth owing to *nausea and vomiting, dysphagia, severe weakness, or coma*
    - There is *malignant bowel obstruction* in patients for whom further surgery is inappropriate (avoiding the need for an intravenous infusion or for insertion of a nasogastric tube)
    - When the patient *does not wish* to take regular medication by mouth.
- **Note:** doses differ between continuous subcutaneous infusions compared to one-off subcutaneous injections (please check!)

# Palliative prescribing

- Be familiar with the “**prescribing in palliative care**” section in the BNF
- Contains generic advice on
  - Pain management
  - Opioid conversions
  - Symptom control

NIC

Guidance

BNF

Read about

NICE > B

British

Key information  
of medicines

Dr

Drug  
medicines

# Continuous subcutaneous infusions

Although drugs can usually be administered *by mouth* to control the symptoms of advanced cancer, the administration of drugs by subcutaneous infusion has led to the use of continuous subcutaneous infusions to give a *continuous* infusion of drugs to control symptoms with little or no sedation.

Indications for the use of continuous subcutaneous infusions are:

- the patient is unable to take drugs by mouth (*dysphagia*, severe nausea and vomiting)
- there is *malignant* obstruction of the gastrointestinal tract (inappropriate for nasogastric tube)
- occasionally with severe pain

## Nausea and vomiting

[Haloperidol](#) and [levomepromazine](#) can both be given as a *subcutaneous infusion* but sedation can limit the dose of [levomepromazine](#).

Cyclizine is particularly likely to precipitate if mixed with diamorphine or other drugs (see under Mixing and compatibility, below)

[Metoclopramide hydrochloride](#) can cause skin reactions.

[Octreotide](#), which stimulates water and electrolyte absorption and inhibits water secretion in the small bowel, can be used by subcutaneous infusion to reduce intestinal secretions and to reduce vomiting due to bowel obstruction.

## Pain control

**Case presentation**

A 72-year-old man presents to the resuscitation room at 2am, tachypnoeic and gasping for breath. **PMH.** STEMI 1 year ago. CABG, CKD. **DH.** Ramipril 5 mg orally daily, bendroflumethiazide 2.5 mg orally daily; amlodipine 10 mg orally daily, aspirin 75 mg orally daily, atorvastatin 40 mg orally nightly.

**On examination**

Temperature 37°C, HR 130/min and regular, BP 140/80 mmHg, JVP raised, RR 30/min, O<sub>2</sub> sat 95% on 15L, HS difficult to hear, chest sounds crackles bilaterally. Pitting oedema of lower limbs.

**Investigations**

Na<sup>+</sup> 138mmol/L (137–144), K<sup>+</sup> 3.7mmol/L (3.5–4.9), U 4.0 mmol/L (2.5–7.0), eGFR 44.  
ECG sinus tachycardia. CXR bilateral pleural effusions, cardiomegaly.

**Question**

Select the *most appropriate* management option at this stage.  
(mark it with a tick)

**MANAGEMENT OPTIONS**

|          |                                                     |
|----------|-----------------------------------------------------|
| <b>A</b> | 0.9% sodium chloride 1 L intravenously over 6 hours |
| <b>B</b> | Aspirin 300 mg orally and clopidogrel 600 mg orally |
| <b>C</b> | Bisoprolol 2.5 mg orally                            |
| <b>D</b> | Furosemide 80 mg intravenously by slow injection    |
| <b>E</b> | Isosorbide mononitrate 120 mg orally                |

☐☐☐☒☐**Answer box****Option A** Justification

IV fluids may exacerbate acute heart failure

**Option B** Justification

Antiplatelets will not help in acute heart failure.

**Option C** Justification

Although beta blocker provide prognostic benefits in the long-term, it is not first line treatment to be added in the acute phase of heart failure.

**Option D** Justification

Furosemide is necessary to treat this patients acute heart failure. As a powerful loop diuretic it will promote a rapid diuresis which will improve is respiratory symptoms by removing excess load from the circulatory system. Larger doses of furosemide is occasionally required.

**Option E** Justification

Although a nitrate is indicated in this case. Oral nitrate therapy is not appropriate in this setting. Instead GTN infusion will help in acute heart failure by improving cardiovascular functioning. GTN is a powerful vasodilator and acts in Acute Heart Failure by reducing left ventricular

**Case presentation**

A 36-year-old man has been admitted with a moderately severe lower respiratory tract pneumonia treated with co-amoxiclav 1.2 g intravenously 8-hrly and oral clarithromycin 500 mg orally 12-hrly. **SH.** He also reports drinking alcohol daily between 20 to 25 units a day.

He has been initiated on a reducing-dose course of chlordiazepoxide.

**Question**

Select the *most appropriate* information option that should be communicated to the patient.  
(mark it with a tick)

**INFORMATION OPTIONS**

|   |                                                                                                                         |                          |
|---|-------------------------------------------------------------------------------------------------------------------------|--------------------------|
| A | Chlordiazepoxide increases the risk of withdrawal symptoms                                                              | <input type="checkbox"/> |
| B | Chlordiazepoxide is also suitable for long-term management of his alcohol dependence when discharged from hospital care | <input type="checkbox"/> |
| C | Chlordiazepoxide is also used to reverse opiate overdoses                                                               | <input type="checkbox"/> |
| D | The dose of his chlordiazepoxide is calculated based on his level of alcohol dependence                                 | X                        |
| E | The dose of his chlordiazepoxide may need to be changed when he changes from intravenous to oral antibiotics            | <input type="checkbox"/> |

**Answer box****Option A** Justification

Chlordiazepoxide treatment aims to reduce the risk of withdrawal symptoms

**Option B** Justification

Chlordiazepoxide should be a short-term management of preventing alcohol withdrawal symptoms, and not a long-term treatment of dependence

**Option C** Justification

Naloxone is used for opiate overdose. Chlordiazepoxide is a benzodiazepine-class hypnotic/sedative

**Option D** Justification

The starting dose (and rate of reduction) is based on the regular alcohol consumption of the patient

**Option E** Justification

Chlordiazepoxide does not have significant interactions with either co-

# Chlordiazepoxide advice

- Chlordiazepoxide is a benzodiazepine-class hypnotic/sedative used as prophylaxis against alcohol withdrawals (NOT opiate withdrawals)
  - It is NOT prophylaxis against Wernicke's encephalopathy (does NOT contain vitamins)
- Dosing depends on degree of alcohol dependence
- If patients have symptoms of alcohol withdrawals, the dose might be increased
- It is usually prescribed as a reducing-dose regime over several days
- It is not typically prescribed for outpatient use
  - It is NOT to maintain abstinence long-term

# Chlordiazepoxide advice

- **Side effects** are similar to other benzodiazepines
- **Pregnancy** - risk of neonatal withdrawal symptoms when used during pregnancy
- **Breast feeding** - benzodiazepines are present in milk, so ideally not to breast feed while prescribed chlordiazepoxide
- **Hepatic impairment** – dose reduce
- **Renal impairment** – dose reduce
- **Skilled tasks** - Drowsiness may persist the next day and affect performance of skilled tasks

**Case presentation**

An 4-year-old girl is about to have her routine immunisations for DTP (diphtheria, tetanus and pertussis) and poliomyelitis boosters, and her second dose of MMR (measles, mumps and rubella) vaccines. She has had her previous immunisations on schedule.

**PMH.** One episode of febrile seizures during a lower respiratory tract infection 4 months ago.

**Question**

Select the *most appropriate* information option that should be communicated to her carer.  
(mark it with a tick)

**INFORMATION OPTIONS**

|          |                                                                                             |                                     |
|----------|---------------------------------------------------------------------------------------------|-------------------------------------|
| <b>A</b> | Her immunisations should be postponed for at least one year without seizures                | <input type="checkbox"/>            |
| <b>B</b> | Her immunisations should be split over six months, rather in one appointment                | <input type="checkbox"/>            |
| <b>C</b> | Ibuprofen is contraindicated in her age group                                               | <input type="checkbox"/>            |
| <b>D</b> | If pyrexia develops, the parent can give paracetamol for up to two doses 4 to 6 hours apart | <input checked="" type="checkbox"/> |
| <b>E</b> | The febrile seizure is a contraindication for rubella boosters                              | <input type="checkbox"/>            |

**Answer box****Option A** Justification

There is no indication to postpone her immunisations

**Option B** Justification

There is no indication to split her immunizations

**Option C** Justification

Ibuprofen is a suitable alternative to paracetamol

**Option D** Justification

This is the recommended self (parent)-management of post-vaccination pyrexia

**Option E** Justification

Febrile seizures are not absolute contraindications to vaccinations, although additional care should be taken

# Vaccines communications

- Be familiar with treatment summaries → vaccines
  - Know what you can find there
  - Also know how to look up individual vaccines
- Contraindications
  - Confirmed anaphylactic reaction to a preceding dose or component
  - Previous anaphylactic reaction to egg
    - Should not be given tick-borne encephalitis vaccine, and yellow fever vaccine should only be considered under the guidance of a specialist.
  - Live vaccines may be contra-indicated temporarily in:
    - Pregnancy (but where there is a significant risk of exposure to disease, e.g. yellow fever, the need for vaccination usually outweighs risk)
    - Severely immunosuppressed
    - Specialist advice should be sought for those being treated with high doses of corticosteroids, or other immunosuppressive drugs
    - Chemotherapy or generalised radiotherapy.

# Vaccines communications

- Acute illness
  - May be postponed if fever or systemic upset.
- Breast-feeding
  - Usually not contraindicated, but see individual vaccines.
- HIV-positive individuals should **not** receive:
  - BCG, influenza nasal spray (unless receiving stable antiretroviral therapy), typhoid (oral), yellow fever.
- Patients with bleeding disorders such as haemophilia or thrombocytopenia
  - Vaccines usually given by the intramuscular route should be given by deep subcutaneous injection instead.

# Vaccines communications

- Post-immunisation pyrexia in infants
  - If pyrexia, and the infant seems distressed, paracetamol can be given and, if necessary, a second dose can be given 4–6 hours later.
  - Ibuprofen can be used if paracetamol is unsuitable.
  - The parent should seek medical advice if the pyrexia persists.
- Predisposition to neurological problems
  - History of stable neurological disorders, convulsions or *febrile* convulsions is **not** a contra-indication to immunisation (with precautions)
  - With a ***still evolving neurological problem***, including poorly controlled epilepsy, immunisation should be *deferred* and referred to a specialist.

**Case presentation**

A 67-year-old man with a new diagnosis of atrial fibrillation was assessed for his risk of thromboembolic disease, and the patient-doctor decision was to start warfarin.

**Question**

Select the *most appropriate* information option that should be communicated to the patient.  
(mark it with a tick)

**INFORMATION OPTIONS**

|   |                                                                                   |                                     |
|---|-----------------------------------------------------------------------------------|-------------------------------------|
| A | If a warfarin dose is missed, it is appropriate to double the dose the next day   | <input type="checkbox"/>            |
| B | If a warfarin dose is missed, it is appropriate to take the dose later in the day | <input checked="" type="checkbox"/> |
| C | INR is a blood test that indicates long-term control of anti-coagulation          | <input type="checkbox"/>            |
| D | Warfarin commonly causes nausea and vomiting                                      | <input type="checkbox"/>            |
| E | Warfarin should be taken after food to prevent gastritis                          | <input type="checkbox"/>            |

**Answer box**

|                                                                                                                                                       |               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| Option A                                                                                                                                              | Justification |
| Doubling the dose significantly increases the risk of haemorrhage                                                                                     |               |
| Option B                                                                                                                                              | Justification |
| This is the appropriate advice                                                                                                                        |               |
| Option C                                                                                                                                              | Justification |
| INR is only a measure of short-term control                                                                                                           |               |
| Option D                                                                                                                                              | Justification |
| Warfarin can (rarely/very rarely) result in nausea/vomiting. Even if true, to inform patient of correct way of taking drug is <i>most appropriate</i> |               |
| Option E                                                                                                                                              | Justification |
| Gastritis is not a common side effect of warfarin, and is unlikely to be improved by food.                                                            |               |

# Warfarin advice

- Good resource at <https://www.nhs.uk/conditions/warfarin/>
  - Have a read before the exam, of course you can't access it during the exam
- Patients should be given a **patient-held information booklet** ('warfarin card')
- Caution about drug-drug **interactions** including over-the-counter medication/supplements (and drug-food interactions, such as vitamin K-supplements and foods, EtOH, certain fruits)
- **Side effects**
  - Discuss bleeding risk, and patient to report any abnormal bleeding, and unusual headaches
  - Seek urgent medical attention if you're taking warfarin and you have a fall or accident, experience a significant blow to your head, are unable to stop any bleeding, have signs of bleeding, such as bruising
  - Skin rashes and hair loss are also common side effects
- Discuss **teratogenicity** and contraception
- “Appears safe in **breast feeding**”

# Warfarin advice

- **Renal impairment**
  - use with caution and needs and increase INR monitoring with severe impairment
- **Hepatic impairment**
  - avoid in severe impairment, especially if prothrombin time is already prolonged
- **Missed doses**
  - If evening doses is missed, take on the same day if remembered before midnight on the same day
  - If midnight has passed, leave that dose and take your normal dose the next day at the usual time.
- **Monitoring**
  - INR determined daily or on alternate days in early days, *then* at longer intervals (depending on response), *then* up to every 12 weeks.
  - Change in clinical condition, e.g liver disease, renal disease, intercurrent illness, or drug administration, necessitates more frequent testing
  - INR only indicates short-term control



### Case presentation

A 35 year-old man was admitted to hospital. He has been requires 6 micrograms/kg/minute drug X intravenously.

He weighs 78kg.

Drug X is available as a 100mg/25ml solution for infusion.

### Calculation

What rate (mL/hr, to the closest 0.1 mL/hr) of Drug X should the patient be given?

(Write your answer in the box below)

Answer

7.0

mL/hr

### Answer box

#### Correct answer

7.0 mL/hr

#### Working

Dose-per-time = 6 micrograms/kg/min x 78kg  
= 468 micrograms/min  
= (468\*60) micrograms/hr  
= 28,080 micrograms/hr  
= 28.08 mg/hr

Concentration = 100mg / 25ml  
= 4 mg/mL

Rate = Dose-per-unit-time / Concentration  
Rate = 28.08 mg/hr / 4 mg/mL  
= 7.02 mL/hr  
= 7.0 mL/hr (to the nearest 0.1 ml/hr)



### Case presentation

A 26-year-old man with type I diabetes mellitus is suffering a hypoglycaemic episode. He is drowsy and unable to orally consume glucose. He was given 50 ml of 20% glucose intravenously.

### Calculation

How much glucose was given?  
(Write your answer in the box below)

Answer

10

grams

### Answer box

#### Correct answer

10 grams

#### Working

20% (w/v) = 20g/100ml  
= 0.2g/ml  
Therefore 50ml provides 0.2g/ml x 50ml = 10g

# Calculations with percentages

## Conversions

- $100\% = 1 \text{ g/mL}$
- $1\% = 1\text{g}/100\text{mL}$
- (Or however you prefer to remember)
- But if you cannot remember on the day, the BNF often as a conversion for the specific drug

Home > Drugs > GLUCOSE

## GLUCOSE

|                               |                                        |
|-------------------------------|----------------------------------------|
| Indications and dose          | Cautions                               |
| Interactions                  | Side-effects                           |
| Directions for administration | Prescribing and dispensing information |
| Exceptions to legal category  | Medicinal forms                        |

### Indications and dose

Establish presence of gestational diabetes

By mouth

**For Adult**  
Test dose 75 g, anhydrous glucose to be given to the fasting measured at intervals, to be given with 200–300 mL fluid.

Oral glucose tolerance test

### Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

Forms available from special-order manufacturers include: oral solution, solution for injection, solution for infusion

[Solution for infusion](#), [Oral solution](#), [Oral gel](#), [Infusion](#)

Home > Drugs > GLUCOSE > Medicinal forms

## GLUCOSE

|                                       |                               |
|---------------------------------------|-------------------------------|
| <a href="#">Solution for infusion</a> | <a href="#">Oral solution</a> |
| <a href="#">Oral gel</a>              | <a href="#">Infusion</a>      |

### Solution for infusion

All products

**Glucose 20% solution for infusion 100ml vials (HameIn Pharmaceuticals Ltd)**

| Active ingredients                | Size | Unit       | NHS indicative price | Drug tariff | Drug tariff price |
|-----------------------------------|------|------------|----------------------|-------------|-------------------|
| • Glucose anhydrous 200mg per 1ml | 1    | vial (POM) | £5.00                | —           | —                 |

**Glucose 50% solution for infusion 20ml ampoules (A A H Pharmaceuticals Ltd)**

| Active ingredients                | Size | Unit          | NHS indicative price | Drug tariff            | Drug tariff price |
|-----------------------------------|------|---------------|----------------------|------------------------|-------------------|
| • Glucose anhydrous 500mg per 1ml | 10   | ampoule (POM) | £12.00               | Part VIII A Category A | £12.00            |

Glucose 50% solution for infusion 20ml ampoules (Alliance Healthcare Distribution Ltd)

Sometimes you have to scroll down to get your desired solution



### Case presentation

A 6-year-old girl requires an anti-emetic in the emergency department. She is prescribed cyclizine intravenously at a dose of 0.5 mg/kg (maximum dose 25mg). She weighs 20 kg.

Cyclizine comes in 50 mg/ml ampoules.

### Calculation

What volume (microliters) of cyclizine is required?  
(Write your answer in the box below)

Answer

200

microlitres

### Answer box

#### Correct answer

200 microlitres

#### Working

$20\text{kg} \times 0.5\text{mg/kg} = 10\text{ mg}$

$10\text{ mg}/50\text{mg/ml} = 0.2\text{ml} = 200\text{ microliters}$



### Case presentation

A 76-year-old woman with angina has been prescribed GTN via syringe driver at 10 micrograms per minute. The stock GTN is initially provided at 1 mg/mL, which is subsequently diluted 1 in 10.

### Calculation

What is the correct rate (mL/hr) of infusion?  
(Write your answer in the box below)

Answer

6

mL/hr

### Answer box

#### Correct answer

6mL/hr

#### Working

Working concentration =  $1\text{mg/ml} \times 1/10$   
= 0.1mg/ml  
= 100 micrograms/ml

Required dose per hour  
= 10 micrograms/minute  $\times$  60 minutes  
= 600 micrograms/hour

Rate = 600 micrograms/hour / 100 micrograms/ml  
= 6mL/hr

### Case presentation

A 53-year-old woman attends her General Practitioner seeking help for smoking cessation. She has tried over-the-counter nicotine replacement therapy without success. In addition to practical advice, they have agreed to trial varenicline with dose up-titration for a 12 week course.

### Question

Select the adverse effect that is *most likely* to be caused by this treatment.  
(mark it with a tick)

### ADVERSE EFFECT OPTIONS

|   |                       |                                     |
|---|-----------------------|-------------------------------------|
| A | Abnormal dreams       | <input checked="" type="checkbox"/> |
| B | Hyponatraemia         | <input type="checkbox"/>            |
| C | Loss of consciousness | <input type="checkbox"/>            |
| D | Menorrhagia           | <input type="checkbox"/>            |
| E | Suicidal ideation     | <input type="checkbox"/>            |

### Answer box

#### Option A Justification

Abnormal dreams is a common side effect of varenicline, as also expected from many centrally acting drugs (e.g. antidepressants etc). However, listed in BNF as “sleep disorders”

#### Option B Justification

Hyponatraemia is not a listed side effect of varenicline

#### Option C Justification

Listed as “frequency not known” in BNF. This could mean anywhere between “very common” and “very rare”. It is likely to be a rare side effect.

#### Option D Justification

Menorrhagia is listed as an uncommon side effect.

#### Option E Justification

Suicidal ideation is uncommon, but important part of counselling patient (See “Important safety information” section in BNF). However, this

(may exacerbate underlying illness including depression); predisposition to seizures

## Side-effects

### Common or very common

Appetite abnormal; asthenia; chest discomfort; constipation; diarrhoea; dizziness; drowsiness; dry mouth; gastrointestinal discomfort; gastrointestinal disorders; headache; joint disorders; muscle complaints; nausea; oral disorders; pain; skin reactions; **sleep disorders**; vomiting; weight increased

### Uncommon

Allergic rhinitis; anxiety; arrhythmias; behaviour abnormal; burping; conjunctivitis; depression; eye pain; fever; fungal infection; haemorrhage; hallucination; hot flush; hyperglycaemia; influenza like illness; malaise; **menorrhagia**; mood swings; numbness; palpitations; seizure; sexual dysfunction; **suicidal ideation**; sweat changes; thinking abnormal; tinnitus; tremor; urinary disorders

### Rare or very rare

Angioedema; bradyphrenia; coordination abnormal; costochondritis; cyst; diabetes mellitus; dysarthria; eye disorders; feeling cold; glycosuria; muscle tone increased; polydipsia; psychosis; scleral discolouration; severe cutaneous adverse reactions (SCARs); snoring; vaginal discharge; vision disorders

### Frequency not known

Loss of consciousness

Note that the symptom does not always match BNF terminology!

Although very important, the question asks about "frequency"

Could range from "very common" to "very rare".  
You have to make your own clinical judgement

**Case presentation**

A 67-year-old man with chronic heart failure is admitted to hospital after his GP notices that his serum creatinine concentration has become acutely elevated from its baseline value of around 150  $\mu\text{mol/L}$  to 450  $\mu\text{mol/L}$  (60–110) over two weeks.

**Question**

Select the prescription that is *most likely* to be contributing to the acute deterioration in renal function.  
(mark it with a tick)

**PRESCRIPTION OPTIONS**

|   |                                     |
|---|-------------------------------------|
| A | Aspirin 75 mg orally daily          |
| B | Bisoprolol 5 mg orally daily        |
| C | Digoxin 125 micrograms orally daily |
| D | Furosemide 160 mg orally daily      |
| E | Nifedipine LA 60 mg orally daily    |

|                                     |
|-------------------------------------|
| <input type="checkbox"/>            |
| <input type="checkbox"/>            |
| <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> |
| <input type="checkbox"/>            |

**Answer box****Option A** Justification

Aspirin is a non-steroidal anti-inflammatory drug but at this low cardiovascular preventative dose it is unlikely to have any significant effect on renal function.

**Option B** Justification

Bisoprolol has little impact on renal function

**Option C** Justification

Digoxin is a drug that has to be used with care in patients with renal impairment but is not, itself, a cause of renal impairment.

**Option D** Justification

Furosemide is a powerful loop diuretic, use of which can lead to dehydration with consequent impairment of renal function.

**Option E** Justification

Nifedipine is not known to cause renal impairment.

# Acute kidney injury / nephrotoxins

- Need to recognise the difference between medications that
  - May cause a reduction in renal function
    - The aim of this question
    - See next slide
  - Require dose adjustments with reduced renal function
    - E.g. digoxin in this question
  - Both of the above

# Acute kidney injury / nephrotoxins

- List of common (potential) nephrotoxins
  - “POTENTIAL” is important – they *can*, but *not always*
  - This is a non-exhaustive list
    - Diuretics, especially loop diuretics not directly toxic, change renal haemodynamics
    - ACEi/ARBs not directly toxic, change renal haemodynamics
    - NSAIDs
    - Aspirin and paracetamol in overdose
    - Statins and fibrates (with rhabdomyolysis)
    - Anti-infectives (rarely when oral)
      - Aminoglycosides such as gentamicin
      - Vancomycin
      - Some penicillins and cephalosporins
      - Intravenous anti-fungals such as amphotericin B
      - Certain intravenous antivirals such as acyclovir
    - Radiocontrast agents (possibly)
    - Lithium in overdose
    - Certain immunosuppressants and chemotherapy
  - Of course, not all AKIs are drug-related

**Case presentation**

A 73-year-old woman is being treated in hospital for an exacerbation of chronic obstructive pulmonary disease. **DH**. Theophylline and inhaled salbutamol. Her other current regular in-patient prescriptions are listed (right).

**Question**

Select the prescription that is *most likely* to interact with theophylline.  
(mark it with a tick)

**PRESCRIPTION OPTIONS**

|          |                                             |                                     |
|----------|---------------------------------------------|-------------------------------------|
| <b>A</b> | Ciprofloxacin 500 mg orally 12-hrly         | <input checked="" type="checkbox"/> |
| <b>B</b> | Enoxaparin 40 mg subcutaneously daily       | <input type="checkbox"/>            |
| <b>C</b> | Ipratropium 500 micrograms nebulised 6-hrly | <input type="checkbox"/>            |
| <b>D</b> | Prednisolone 30 mg orally daily             | <input type="checkbox"/>            |
| <b>E</b> | Salbutamol 2.5 mg nebulised 6-hrly          | <input type="checkbox"/>            |

**Answer box****Option A** Justification

Ciprofloxacin is an enzyme inhibitor and increases theophylline levels. Theophylline has a narrow therapeutic index and high levels may precipitate seizures and cardiac dysrhythmias

**Option B** Justification

Enoxaparin has few drug-drug interactions.

**Option C** Justification

Ipratropium does not interact with theophyllines

**Option D** Justification

Prednisolone does not interact significantly with theophyllines

**Option E** Justification

Nebulised drugs rarely have significant interactions with oral drugs



The image shows the homepage of the MedicinesComplete website. The background is a dark blue with a pattern of various pills. The MedicinesComplete logo is in the top left. A search bar in the center contains the text "theophylline ciprofloxacin enoxaparin ipratropium prednisolone salbutamol". To the right of the search bar is a vertical menu with icons and labels: "All Publications", "BNF" (highlighted with a red box), "BNF for Children", and "AHFS Drug Information". In the bottom left, there are icons for "Stockley's Interactions Checker" (crossed out with a red X) and "MC Calculators".

MedicinesComplete

*theophylline ciprofloxacin enoxaparin ipratropium prednisolone salbutamol*

Stockley's Interactions Checker


MC Calculators

All Publications

BNF

BNF for Children

AHFS Drug Information



The image shows the search results page for the same query. The page has a white background. The MedicinesComplete logo is in the top left. The search bar contains the same query. To the right of the search bar are icons for "Stockley's Interactions Checker" and a user profile icon. Below the search bar, the text "Search results for theophylline ciprofloxacin enoxaparin ipratropium prednisolone salbutamol" is displayed. Below this is a button labeled "Stedman's Definition". On the left side, there is a "Filter Results" section with a list of filters: "All Publications 0 Results", "BNF 0 Results" (highlighted with a red box), "Interactions" (highlighted with a red box), "BNF for Children 0 Results", "Unsubscribed Publication", and "AHFS Drug Information 0 Results". The main content area on the right says "There are no results for 'theophylline ciprofloxacin enoxaparin ipratropium prednisolone salbutamol'".

MedicinesComplete

*theophylline ciprofloxacin enoxaparin ipratropium prednisolone salbutamol*

Stockley's Interactions Checker

Search results for *theophylline ciprofloxacin enoxaparin ipratropium prednisolone salbutamol*

Stedman's Definition

Filter Results

All Publications  
0 Results

BNF  
0 Results

Interactions

BNF for Children  
0 Results

Unsubscribed Publication

AHFS Drug Information  
0 Results

There are no results for 'theophylline ciprofloxacin enoxaparin ipratropium prednisolone salbutamol'.

5 results, in alphabetical order, for:

theophylline — ciprofloxacin — enoxaparin — ipratropium — prednisolone —  
salbutamol

#### Ipratropium and Salbutamol

Salbutamol is predicted to increase the risk of glaucoma when given with ipratropium.

Severity: **Moderate**

Evidence: Anecdotal

#### Prednisolone and Salbutamol

Both Salbutamol and Prednisolone can increase the risk of hypokalaemia.

#### Ciprofloxacin and Theophylline

Ciprofloxacin is predicted to increase the exposure to Theophylline. Manufacturer advises monitor and adjust dose.

Severity: **Moderate**

Evidence: Theoretical

#### Prednisolone and Theophylline

Both Theophylline and Prednisolone can increase the risk of hypokalaemia.

#### Salbutamol and Theophylline

Both Salbutamol and Theophylline can increase the risk of hypokalaemia.

Not relevant to THIS question (as does not include theophylline)

You have to decide between these on which is *most important*

(NOTE: The question does not specify the resultant side effect, which may sway your answer)

### Case presentation

A 75-year-old man with multiple myeloma and reactive depression took an overdose of his amitriptyline. On presentation, he was tachycardic and drowsy.

### Investigations

His ECG showed a sinus tachycardia with QRS duration of 130 ms.

### Question

Select the *most appropriate* option for the immediate management of this adverse drug reaction.  
(mark it with a tick)

## MANAGEMENT OPTIONS

- |   |                                            |
|---|--------------------------------------------|
| A | 10% calcium gluconate 10 mls intravenously |
| B | Atropine 3 mg intravenously                |
| C | Haemodialysis                              |
| D | Hydrocortisone 200 mg intravenously        |
| E | Sodium bicarbonate 50 mmol intravenously   |

|                                     |
|-------------------------------------|
| <input type="checkbox"/>            |
| <input type="checkbox"/>            |
| <input type="checkbox"/>            |
| <input type="checkbox"/>            |
| <input checked="" type="checkbox"/> |

## Answer box

### Option A Justification

Calcium gluconate protects cardiac myocytes from the effects of hyperkalaemia.

### Option B Justification

Atropine is indicated to reverse bradycardia.

### Option C Justification

Haemodialysis is indicated for overdoses with likely organ failure in overdoses with a small volume of distribution

### Option D Justification

Hydrocortisone has a role in the emergency treatment of anaphylactic and Addisonian reactions.

### Option E Justification

TCA overdose leads to sodium channel blocking in the myocardium that predisposes to tachyarrhythmias. The first sign of impending cardiovascular complications is prolongation of the QRS complex. Sodium bicarbonate increases TCA protein binding, dislodges TCAs from the sodium channel and increases TCA elimination.

# “Poisoning, emergency treatment”

- Be familiar with the content here. Contains guidance on how to treat overdoses with:

- Aspirin
- Opioids
- Paracetamol
- Tricyclic antidepressants
- SSRIs
- Benzodiazepines
- Beta-blockers
- Calcium channel blockers
- Lithium
- (And many more)

NICE National Institute for Health and Care Excellence

Evidence search | BNF | BNFC | CKS | Journals and databases

Search...

Drugs | Interactions | Treatment Summaries | What's Changed?

Home > Treatment summary > Poisoning, emergency treatment

## Poisoning, emergency treatment

### Overview

These notes provide only an overview of the treatment of poisoning, and it is strongly recommended that either TOXBASE or the UK National Poisons Information Service be consulted when there is doubt about the degree of risk or about management.

### Hospital admission

Patients who have features of poisoning should generally be admitted to hospital. Patients who have taken poisons with delayed action should also be admitted, even if they appear well. Delayed-action poisons include aspirin, iron, paracetamol, tricyclic antidepressants, and co-phenotrope (diphenoxylate with atropine, Lomotil®); the effects of modified-release preparations are also delayed. A note of all relevant information, including what

Relat

- AC
- AD
- AS
- AT
- CA
- CALCIUM GLUCONATE
- CARBAMAZEPINE
- CHARCOAL, ACTIVATED
- CO-PHENOTROPE
- DESFERRIOXAMINE MESILATE
- DIAZEPAM
- DICOBALT EDEATE
- FLUANTH

Scroll down and be familiar with contents

## Antidepressant poisoning

### Tricyclic and related antidepressants

Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. Metabolic acidosis may complicate severe poisoning; delirium with confusion, agitation, and visual and auditory hallucinations are common during recovery.

Assessment in hospital is strongly advised in case of poisoning by tricyclic and related antidepressants but symptomatic treatment can be given before transfer. Supportive measures to ensure a clear airway and adequate ventilation during transfer are mandatory. Intravenous lorazepam or intravenous diazepam (preferably in emulsion form) may be required to treat convulsions. Activated charcoal given within 1 hour of the overdose reduces absorption of the drug. Although arrhythmias are worrying, some will respond to correction of hypoxia and acidosis. The use of anti-arrhythmic drugs is best avoided, but intravenous infusion of sodium bicarbonate can arrest arrhythmias or prevent them in those with an extended QRS duration. Diazepam given by mouth is usually adequate to sedate delirious patients but large doses may be required.

**Case presentation**

A 49-year-old woman is in hospital while she commences lithium carbonate (Priadel®) 1 g orally daily for bipolar disorder. She has been noted to have mild tremors and slightly slurred speech.

**PMH.** Hypertension. **DH.** Ramipril 5mg orally daily.

A level was taken 12 hours after her fourth dose and has come back as 1.35 mmol/L (target range 0.4-1 mmol/L). Initially she is given 0.9% sodium chloride 1 L intravenously over 4 hours, and her lithium treatment withheld for one day. Her lithium levels the following day is 1.0 mmol/L and her symptoms are resolving.

**Question**

Select the *most appropriate* decision option with regard to optimising her lithium level based on these data.  
(mark it with a tick)

**DECISION OPTIONS**

| A | Continue Priadel® at 1 g orally daily                               | <input type="checkbox"/>            |
|---|---------------------------------------------------------------------|-------------------------------------|
| B | Reduce Priadel® to 500 mg orally daily                              | <input checked="" type="checkbox"/> |
| C | Reduce ramipril to 2.5 mg orally daily                              | <input type="checkbox"/>            |
| D | Switch from Priadel® 1 g orally daily to Camcolit® 1 g orally daily | <input type="checkbox"/>            |
| E | Switch from ramipril to losartan 12.5 mg orally daily               | <input type="checkbox"/>            |

**Answer box****Option A** Justification

The current lithium levels is related to the 0.9% sodium chloride treatment, and does not reflect what her levels would be if she persists with the 1g dose.

**Option B** Justification

A reduction in dose to 500mg should ensure that this lady can continue taking her ramipril and lithium, however, the level needs rechecking in 3-4days. It is always wise to seek specialist advice on using this toxic drug with a narrow therapeutic index.

**Option C** Justification

ACE inhibitors are effective in treating high blood pressure, but reduce the excretion of lithium salts. Reducing the Ramipril may worsen BP control.

**Option D** Justification

Switching lithium salts is tricky and not recommended as each preparation has a different bioavailability profile.

**Option E** Justification

ACE inhibitors are effective in treating high blood pressure, but reduce the excretion of lithium salts. Reducing the Ramipril may worsen BP control.

**Case presentation**

A 35-year old, 70-kg man with no known co-morbidities presents to Accident and Emergency stating he has taken a deliberate overdose of 20 tablets of 500 mg paracetamol. He reports that he took them 6 hours, and took all the tablets within 5 minutes. He is currently asymptomatic and compliant with treatment.

**Investigations (at 6 hours post-ingestion)**

Bili 14  $\mu\text{mol/L}$  (1–22), ALT 30 U/L (5–35), AST 25 U/L (1–31), alk phos 82 U/L (45–105), GGT 42 U/L (<50).  
INR 1.1 (<1.4)

Plasma-paracetamol concentration 0.38 mmol/L  
Plasma salicylate not detected

He is also being provided appropriate psychological support.

**Question**

Select the *most appropriate* decision option with regard to the paracetamol overdose based on these data.  
(mark it with a tick)

**DECISION OPTIONS**

| DECISION OPTIONS |                                                |   |
|------------------|------------------------------------------------|---|
| <b>A</b>         | 0.9% sodium chloride as gastric lavage         |   |
| <b>B</b>         | Acetylcysteine 10.5g intravenously over 1 hour |   |
| <b>C</b>         | Activated charcoal 50mg orally                 |   |
| <b>D</b>         | Methionine 500mg orally 4hr-ly                 |   |
| <b>E</b>         | No medical treatment required                  | X |

**Answer box****Option A** Justification

Gastric lavage is now rarely required.  
May be consider within the 1<sup>st</sup> hour for substances that cannot be removed effectively by other means (e.g. iron) in life-threatening doses.

**Option B** Justification

He does not require treatment as below the treatment line. This would however be the correct treatment if his plasma paracetamol concentrations were above the treatment line

**Option C** Justification

May be considered if potentially toxic doses consumed within the last hour

**Option D** Justification

Oral methionine is a rarely used second-line (unlicensed) alternative to N-acetylcysteine for paracetamol overdoses.

**Option E** Justification

He does not require treatment as below the treatment line

# Paracetamol OD

- Know where to find information on overdoses
- Treatment summaries > Treatment summaries by body system > poisoning
- Understand what to do for patients who present:
  - Within one hour
  - Within 4 hours
  - Within 4-24 hours
  - After 24 hours
  - Staggered overdose, uncertain time of overdose and therapeutic excess

# “Poisoning, emergency treatment”

- Be familiar with the content here. Contains guidance on how to treat overdoses with:
  - Aspirin
  - Opioids
  - Paracetamol
  - Tricyclic antidepressants
  - SSRIs
  - Benzodiazepines
  - Beta-blockers
  - Calcium channel blockers
  - Lithium
  - (And many more)

NICE National Institute for Health and Care Excellence

Evidence search | BNF | BNF C | C | Journals and databases

Search...

Drugs | Interactions | Treatment Summaries | What's Changed?

Home > Treatment summary > Poisoning, emergency treatment

**Poisoning, emergency treatment**

**Overview**

These notes provide only an overview of the treatment of poisoning, and it is strongly recommended that either TOXBASE or the UK National Poisons Information Service be consulted when there is doubt about the degree of risk or about management.

**Hospital admission**

Patients who have features of poisoning should generally be admitted to hospital. Patients who have taken poisons with delayed action should also be admitted, even if they appear well. Delayed-action poisons include aspirin, iron, paracetamol, tricyclic antidepressants, and co-phenotrope (diphenoxylate with atropine, Lomotil®); the effects of modified-release preparations are also delayed. A note of all relevant information, including what

Relat

- AS
- AS
- AS
- AS
- AS
- C
- CALCIUM GLUCONATE
- CARBAMAZEPINE
- CHARCOAL ACTIVATED
- CO-PHENOTROPE
- DESFERRIOXAMINE
- DIAZEPAM
- DICOBALT EDEDATE
- ...

Scroll down and be familiar with contents

**Paracetamol poisoning**

In cases of **intravenous paracetamol poisoning** contact the National Poisons Information Service for advice on risk assessment and management.

Toxic doses of **paracetamol** may cause severe hepatocellular necrosis and, much less frequently, renal tubular necrosis. Nausea and vomiting, the only early features of poisoning, usually settle within 24 hours. Persistence beyond this time, often associated with the onset of right subcostal pain and tenderness, usually indicates development of hepatic necrosis. Liver damage is maximal 3–4 days after **paracetamol** overdose and may lead to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, and death. Therefore, despite a lack of significant early symptoms, patients who have taken an overdose of **paracetamol** should be transferred to hospital urgently.

To avoid underestimating the potentially toxic **paracetamol** dose ingested by obese patients who weigh more than 110 kg, use a body-weight of 110 kg (rather than their actual body-weight) when calculating the total dose of **paracetamol** ingested (in mg/kg).


**Acetylcysteine** protects the liver if infused up to, and possibly beyond, 24 hours. It is most effective if given within 8 hours of ingestion, after which effectiveness decreases. **Acetylcysteine** by mouth [unlicensed route] is an alternative if intravenous **acetylcysteine** is not available. Contact the National Poisons Information Service for advice.

Neonates less than 45 weeks corrected gestational age may be more susceptible to toxicity, therefore, treatment with **acetylcysteine** should be considered in all **paracetamol** overdoses, and advice should be sought from the National Poisons Information Service.

**Acute overdose**

Hepatotoxicity may occur after a single ingestion of more than 150 mg/kg **paracetamol** taken in less than 1 hour. Rarely, hepatotoxicity may develop with single ingestions as low as 75 mg/kg of **paracetamol** taken in less than 1 hour. Patients who have ingested 75 mg/kg or more of **paracetamol** in less than 4 hours should be considered for treatment.

Big section Be familiar!



**Case presentation**

A 72-year-old man attends the anti-coagulation clinic for routine monitoring and is found to have an INR of 7.9. He has no signs of bleeding. He usually takes warfarin 3 mg orally daily to maintain an INR of 2.5 for atrial fibrillation.

**Question**

Select the *most appropriate* decision option with regard to the warfarin prescription based on these data.  
(mark it with a tick)

**DECISION OPTIONS**

| DECISION OPTIONS |                                                                          |                                     |
|------------------|--------------------------------------------------------------------------|-------------------------------------|
| <b>A</b>         | Continue warfarin at 2 mg daily                                          | <input type="checkbox"/>            |
| <b>B</b>         | Omit warfarin for 2 doses and then restart at lower dose                 | <input checked="" type="checkbox"/> |
| <b>C</b>         | Omit warfarin, give vitamin K 3 mg intravenously                         | <input type="checkbox"/>            |
| <b>D</b>         | Omit warfarin, give vitamin K 5 mg and prothrombin complex intravenously | <input type="checkbox"/>            |
| <b>E</b>         | Omit warfarin, give vitamin K 5 mg orally                                | <input type="checkbox"/>            |

**Answer box****Option A** Justification

This is inappropriate and may lead to excessive anticoagulation for a prolonged period

**Option B** Justification

This is appropriate treatment for INR 5-8 with no bleeding.

**Option C** Justification

This is appropriate treatment for INR >8 with no bleeding.

**Option D** Justification

This is appropriate treatment for INR >8 with minor bleeding.

**Option E** Justification

This is appropriate treatment for raised INR with major bleeding

# Warfarin, high INR

- Be familiar with looking at Treatment summaries → Oral anticoagulants
- Know what you can find there
- Contains generic advice on
  - Target INR
  - Duration of treatment with DVTs
  - Action with high INRs / bleeding
  - Peri-operative management

# Oral anticoagulants

## Overview

Scroll  
down



The main use of anticoagulants is to prevent thrombus formation or extension of an existing thrombus in the slower-moving venous side of the circulation, where the thrombus consists of a fibrin web enmeshed with platelets and red cells.

Anticoagulants are of less use in preventing thrombus formation in arteries, for in faster-flowing vessels thrombi are composed mainly of platelets with little fibrin.

embolism; long-term anticoagulation may be required.

## Haemorrhage

The main adverse effect of all oral anticoagulants is haemorrhage. Checking the INR and omitting doses when appropriate is essential; if the anticoagulant is stopped but not reversed, the INR should be measured 2–3 days later to ensure that it is falling. The cause of an elevated INR should be investigated. The following recommendations (which take into account the recommendations of the British Society for Haematology Guidelines on Oral Anticoagulation with Warfarin—fourth edition. *Br J Haematol* 2011; **154**: 311–324) are based on the result of the INR and whether there is major or minor bleeding; the recommendations apply to adults taking warfarin:

- Major bleeding—stop [warfarin sodium](#); give [phytomenadione](#) (vitamin K<sub>1</sub>) by slow intravenous injection; give [dried prothrombin complex](#) (factors II, VII, IX, and X); if dried prothrombin complex unavailable, fresh frozen plasma can be given but is less effective; recombinant factor VIIa is not recommended for emergency anticoagulation reversal

# Need to know:

## 1.INR

## 2.Severity of bleeding

| Bleeding                            | INR       | Action                                                                                                                                                                                                         |
|-------------------------------------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Major<br>(limb or life-threatening) | Any       | Stop warfarin<br>Give phytomenadione (vitamin K <sub>1</sub> ) 5 mg slow i.v.<br>Give dried prothrombin complex 25–50 units/kg i.v.<br>(If dried prothrombin complex unavailable, give FFP but less effective) |
| Minor                               | >8.0      | Stop warfarin<br>Give phytomenadione (vitamin K <sub>1</sub> ) 1–3 mg slow i.v. (Repeat dose of phytomenadione if INR still too high after 24 hours)<br>Restart warfarin when INR <5.0                         |
|                                     | 5.0 – 8.0 | Stop warfarin<br>Give phytomenadione (vitamin K <sub>1</sub> ) 1–3 mg slow i.v.<br>Restart warfarin when INR <5.0                                                                                              |
| Nil                                 | >8.0      | Stop warfarin<br>Give phytomenadione (vitamin K <sub>1</sub> ) 1–5 mg <u>p.o.</u><br>(Repeat dose of phytomenadione if INR still too high after 24 hours)<br>Restart warfarin when INR <5.0                    |
|                                     | 5.0 – 8.0 | Withhold 1 or 2 doses of warfarin<br>Reduce subsequent maintenance dose                                                                                                                                        |

Also, you can search  
 “phytomenadione”  
 But contains less info e.g.

- How much dried prothrombin complex
- What to do when no bleeding and INR 5-8

Home > Drugs > PHYTOMENADIONE

## PHYTOMENADIONE

Indications and dose

Cautions

Pregnancy

Hepatic impairment

Medicinal forms

Unlicensed use

Side-effects

Breast feeding

Directions for administration

Related Treatment Summaries

- Oral anticoagulants
- Other drugs in the class vitamin k
- MENADIOL SODIUM PHOSPHATE

### Indications and dose

Major bleeding in patients on warfarin (in combination with dried prothrombin complex or fresh frozen plasma)

By slow intravenous injection

For Adult  
 5 mg for 1 dose, stop warfarin treatment.

bleeding in patients on warfarin  
 action

In treatment, dose may be repeated if INR still too high after 24 hours, restart when INR <5.

eding in patients on warfarin

s preparation to be used orally, stop warfarin treatment, repeat dose if INR still too high, restart warfarin treatment when INR <5.

nor bleeding in patients on warfarin  
 action

In treatment, restart warfarin treatment when INR <5.

ulation prior to elective surgery (after warfarin stopped)

s preparation to be used orally, dose to be given the day before surgery if INR >1.5.  
 ulation prior to emergency surgery (when surgery can be delayed 6-12

n

e, if surgery cannot be delayed, dried prothrombin complex can be given in addition to id the INR checked before surgery.

### Indications and dose

Major bleeding in patients on warfarin (in combination with dried prothrombin complex or fresh frozen plasma)

By slow intravenous injection

For Adult  
 5 mg for 1 dose, stop warfarin treatment.

INR > 8.0 with minor bleeding in patients on warfarin

By slow intravenous injection

For Adult  
 1-3 mg, stop warfarin treatment, dose may be repeated if INR still too high after 24 hours, restart warfarin treatment when INR <5.

INR > 8.0 with no bleeding in patients on warfarin

By mouth

**Case presentation**

A 24-year old man is having his diabetic control reviewed. He is currently asymptomatic. **PMH.** Type I diabetes. **DH.** Basal-bolus insulin.

He has concerns that his lunchtime dose is too high.

**Question**

Select the *most appropriate* monitoring option to assess the effects of lunchtime dose of insulin.  
(mark it with a tick)

**MONITORING OPTIONS**

|   |                                          |
|---|------------------------------------------|
| A | Bedtime capillary blood glucose          |
| B | Haemoglobin A1c                          |
| C | Post-lunch capillary blood glucose       |
| D | Pre-evening meal capillary blood glucose |
| E | Pre-lunch capillary blood glucose        |

|   |
|---|
|   |
|   |
|   |
| x |
|   |

**Answer box****Option A** Justification

Bedtime capillary blood glucose would be a good measure of evening meal dose

**Option B** Justification

Haemoglobin A1c would assess long-term control

**Option C** Justification


While post-lunch capillary blood glucose is influenced by lunchtime dose, it is not the usual way of assessing impact (usually the next pre-meal glucose level). Furthermore, if his "dose is too high", a post-meal glucose level is unlikely to detect hypoglycaemia.

**Option D** Justification

The pre-evening meal capillary blood glucose would be the most likely time point to detect hypoglycaemia relating to the lunch-time dose

**Option E** Justification

The pre-lunch glucose level is influenced by the breakfast dose



Basal-bolus therapy

|                   | MAIN influence on blood glucose |
|-------------------|---------------------------------|
| Pre-breakfast     | Basal dose                      |
| Post-breakfast    | Breakfast dose                  |
| Pre-lunch         | (Breakfast and basal dose)      |
| Post-lunch        | Lunch dose                      |
| Pre-evening meal  | (Lunch and basal dose)          |
| Post-evening meal | Evening meal dose               |
|                   |                                 |

**Case presentation**

A 78-year-old woman is commenced on lithium as prophylaxis for bipolar affective disorder.

**Question**

Select the *most appropriate* monitoring option that should be arranged for this patient.  
(mark it with a tick)

**MONITORING OPTIONS****A** Eye movements**B** Fractional renal sodium excretion**C** Hand-grip strength**D** Pulmonary function tests**E** Thyroid function☐☐☐☐☒**Answer box****Option A** Justification

Nystagmus is a feature of toxicity but is not specific enough to be able to be used for monitoring

**Option B** Justification

Fractional renal sodium excretion is occasionally used to evaluate acute kidney injury. Lithium is associated with diabetes insipidus and 6-monthly renal function is mandated.

**Option C** Justification

Lithium can cause tremor but not muscular weakness

**Option D** Justification

Lithium is not associated with pulmonary disease

**Option E** Justification

Long-term lithium can affect thyroid function, and therefore should be checked 6-monthly or when symptoms of thyroid disease occur.

Search...

[Drugs](#) | [Interactions](#) | [Treatment Summaries](#) | [What's C](#)

Home > Drugs > LITHIUM CARBONATE

# LITHIUM CARBONATE

[Indications and dose](#)

[Cautions](#)

[Side-effects](#)

[Pregnancy](#)

[Renal impairment](#)

[Treatment cessation](#)

[Medicinal forms](#)

[Contra-indications](#)

[Interactions](#)

[Conception and contraception](#)

[Breast feeding](#)

[Monitoring requirements](#)

[Patient and carer advice](#)

## Monitoring requirements

For all LITHIUM SALTS

### Therapeutic drug monitoring

#### Serum concentrations

Lithium salts have a narrow therapeutic/toxic ratio and should therefore not be prescribed unless facilities for monitoring serum-lithium concentrations are available.

Samples should be taken 12 hours after the dose to achieve a serum-lithium concentration of 0.4–1 mmol/litre (lower end of the range for maintenance therapy and elderly patients).

A target serum-lithium concentration of 0.8–1 mmol/litre is recommended for acute episodes of mania, and for patients who have previously relapsed or have sub-syndromal symptoms. It is important to determine the optimum range for each individual patient.

Routine serum-lithium monitoring should be performed weekly after initiation and after each dose change until concentrations are stable, then every 3 months thereafter. Additional serum-lithium measurements should be made if a patient develops significant intercurrent disease or if there is a significant change in a patient's sodium or fluid intake.

#### Monitoring of patient parameters

Manufacturer advises to assess renal, cardiac, and thyroid function before treatment initiation. An ECG is recommended in patients with cardiovascular disease or risk factors for it. Body-weight or BMI, serum electrolytes, and a full blood count should also be measured before treatment initiation.

Monitor body-weight or BMI, serum electrolytes, eGFR, and thyroid function every 6 months during treatment, and more often if there is evidence of impaired renal or thyroid function, or raised calcium levels. Manufacturer also advises to monitor cardiac function regularly.

**Case presentation**

A 68-year-old man with type 2 diabetes mellitus has had his long- and short-acting insulin adjusted upwards in clinic 5 months ago. At clinic today he reports he took his insulin as prescribed.

**Question**

Select the *ONE most appropriate* monitoring options to assess the impact of this treatment.  
(mark it with a tick)

**MONITORING OPTIONS**

| MONITORING OPTIONS |                                 |                                     |
|--------------------|---------------------------------|-------------------------------------|
| <b>A</b>           | Assessing peripheral neuropathy | <input type="checkbox"/>            |
| <b>B</b>           | Blood glucose diary             | <input checked="" type="checkbox"/> |
| <b>C</b>           | Body mass index                 | <input type="checkbox"/>            |
| <b>D</b>           | Fasting blood glucose           | <input type="checkbox"/>            |
| <b>E</b>           | Fasting lipid profile           | <input type="checkbox"/>            |

**Answer box****Option A** Justification

This must be assessed at every visit, but is not a method used to judge compliance to insulin treatment.

**Option B** Justification

Reviewing a blood glucose diary for evidence of good blood sugar levels is important, as is deciding if any hypoglycaemic episodes have occurred.

**Option C** Justification

Body mass index will not tell you how compliant the patient has been with their insulin regime.

**Option D** Justification

Following diagnosis of diabetes mellitus, fasting blood glucose is not a good representation of glucose control, and definitely not long-term control

**Option E** Justification

Lipid profile will not tell you anything about his compliance with insulin.

**Case presentation**

A 28-year-old woman attends her General Practitioner to discuss options for contraception. **PMH.** None. **DH.** None.

After discussion, they agree to start Levest® 150/30 tablets (levonorgestrel 150 micrograms / ethinylestradiol 30 micrograms), 1 active tablet once daily for 21 days, followed by 1 inactive tablet once daily for 7 days.

**Question**

Select the *most appropriate* monitoring option that should be arranged routinely for this patient.  
(mark it with a tick)

**MONITORING OPTIONS**

|   |                      |                                     |
|---|----------------------|-------------------------------------|
| A | Blood pressure       | <input checked="" type="checkbox"/> |
| B | Breast examination   | <input type="checkbox"/>            |
| C | Liver function tests | <input type="checkbox"/>            |
| D | Oxygen saturations   | <input type="checkbox"/>            |
| E | Urine microscopy     | <input type="checkbox"/>            |

**Answer box**

|                                                                     |               |
|---------------------------------------------------------------------|---------------|
| Option A                                                            | Justification |
| COCPs can increase BP and should be stopped if BP > 160/95 mmHg     |               |
| Option B                                                            | Justification |
| There is no indication for breast examination routinely             |               |
| Option C                                                            | Justification |
| COCP can cause deranged LFTs but it is not routinely monitored      |               |
| Option D                                                            | Justification |
| COCP is a major risk factor for PE but this can not be screened for |               |
| Option E                                                            | Justification |
| There is no indication for urine microscopy screening               |               |

# Reminder

- Full results to follow from Tom Schindler / Dr Nimesh Patel